BURLINGTON, Mass.--(BUSINESS WIRE)--Nipro Corporation ([Stock Index]: [TYO: 8086]) today announced it has
signed a definitive agreement to acquire Infraredx, Inc., (.infraredx.com),
an intravascular imaging company committed to advancing the diagnosis
and management of coronary artery disease globally. Buy Zestril (Lisinopril) with no Rx Nipro Corporation
offers products and technologies that meet the needs of patients and
medical professionals in a wide range of fields, such as artificial
organs, circulatory devices, test/diagnostic agents, injection/infusion
solutions, ethical pharmaceuticals, and medical glass products. About Biaxin (Clarithromycin) without Rx The
agreement combines the strengths of Nipro Corporation and Infraredx, by
leveraging Nipro s strong global cardiovascular portfolio and resources
along with Infraredx’s industry expertise in near infrared spectroscopy
(NIRS) and intravascular ultrasound. Buy Hyzaar (Losartan / Hydrochlorothiazide) with no Rx The agreement will help introduce
Nipro’s cardiovascular product line into the United States, and continue
Infraredx’s mission to empower interventional cardiologists with the
advanced imaging tools required to predict heart attacks and prevent
them—catalyzing a global shift from reactive treatment to proactive care
of coronary artery disease.
“Company Founder James E. Faverin with no prescription Muller, MD, and the Infraredx management team
have empowered interventional cardiologists with the NIRS-IVUS imaging
system, which is approved to detect the lipid-core plaques that cause
most heart attacks,” said Yoshihiko Sano, President, Nipro. About Mentat () with no prescription “Nipro and
Infraredx share a strong patient centered focus and the combination of
the companies’ global portfolio and cardiovascular expertise will help
us deliver the most comprehensive imaging solution available to change
how cardiovascular disease is managed. Buy Carnitine online We look forward to bringing
together the two companies to deliver the best of medicine and
innovation.”
“By teaming up with one of the leading global medical equipment
manufacturing companies in the world, Infraredx is able to leverage
Nipro’s global network and vast resources to enhance its presence and
impact a larger audience locally as well globally,” said Jason
Bottiglieri, President and CEO of Infraredx. http://pharmaceutical-journal.blogspot.com “We are pleased to combine
our strengths to meet the demands of the marketplace and continue to
deliver to the medical community cardiovascular imaging systems that
hold the potential to revolutionize the management of cardiovascular
disease.”
Harnessing 30 years of research into the association between heart
attacks and lipid-core plaques, Infraredx has been committed to the
design, manufacturing, and distribution of technologies that address the
needs of practitioners and improve outcomes in the treatment of patients
with coronary artery disease. With ongoing investment in several
landmark global clinical trials, Infraredx’s mission, to enable
cardiologists to predict heart attacks and prevent them, will continue.
The acquisition, which is subject to certain conditions, is expected to
close in October 2015.
About Infraredx
Founded in 1999, Infraredx, Inc., is a privately-funded medical device
company dedicated to helping provide practitioners with the information
needed for enhanced clinical decision making for the treatment of
coronary artery disease. The company is committed to improving the
safety and efficacy of coronary stenting and ultimately serving as part
of a strategy to prevent initial coronary events. Through its TVC
Imaging System™, Infraredx is changing the way coronary artery disease
is diagnosed and treated.
About Nipro
Nipro Corporation, headquartered in Osaka, Japan, has been a world
leader in providing medical products to the healthcare community for
over 50 years. In addition to Nipro-branded products, Nipro provides
manufacturing support to some of the biggest names in the medical field.
This announcement contains forward-looking statements that involve risks
and uncertainties including, among others, the ability to successfully
integrate the two companies, and to realize the synergies and other
perceived advantages resulting from this acquisition.
No comments:
Post a Comment